Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CarMax, Inc (KMX) vs Eli Lilly And Co (LLY) Price & Performance

CarMax, IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

CarMax, Inc vs Eli Lilly And Co — how do they compare? CarMax, Inc trades at $57.8 (market cap $8.26B), while Eli Lilly And Co trades at $1,225.02 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 130.8× CarMax, Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.

KMXLLY
Market Cap
$8.26B$1.08T
Sector
Consumer CyclicalHealth
52-Week High
$62.17$1.24K
52-Week Low
$30.88$639.43
Enterprise Value
$26.77B$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CarMax, Inc

CarMax (KMX) trades at $58.78, up 1.03% today, with a bullish technical signal and strong analyst support. Recent earnings have beaten expectations, with Q3 2025 and Q1 2026 EPS surpassing estimates, though Q2 2025 missed. Revenue remains stable around $26.4 billion, but net income margin is thin at 0.84%. The stock is near its consensus price target of $53.09, with a high target of $66.00. Positive news includes a Zacks Strong Buy rating and partnerships to enhance customer experience.

The outlook for KMX is cautiously optimistic, driven by earnings beats and bullish technicals, but high debt and margin pressures pose risks. Investment opportunity lies in continued execution and market share gains, while risks include competitive pressures and economic sensitivity. Analyst consensus leans Hold, with 68.58% holding, suggesting a wait-and-see approach for further growth confirmation.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CarMax, Inc

CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.

Read more on KMX

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY